Ocular changes induced by chemotherapy;Alterações oculares induzidas pela quimioterapia

Arquivos Brasileiros de Oftalmologia

Volumn 70, Issue 4, 2007, Pages 718-725

  Chaves, Alessandra Pinheiro ^a,b   Gomes, José Álvaro Pereira ^a   Höfling Lima, Ana Luisa ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Chemotherapy adverse effects; Conjunctiva cytology; Drug therapy, mucositis chemically induced; Neoplasms drug therapy

Indexed keywords

EID: 37349075114     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/s0004-27492007000400028     Document Type: Article

References (48)

1. Fraunfelder FT, Meyer SM. Ocular toxicity of antineoplastic agents. Ophthalmology. 1983;90(1):1-3.
2. Loprinzi CL, Foote RL, Michalak J. Alleviation of cytotoxic therapy-induced normal tissue damage. Semin Oncol. 1995;22(2 Suppl 3):95-7.
3. Controle do câncer. uma proposta de integração ensino-serviĉo. Rio de Janeiro: Pró-Onco/NUTES; 1990.
4. Giglio AD. Modalidades terapêuticas para o tratamento do câncer. In: Giglio AD. Câncer: introdução so seu estudo e tratamento. São Paulo: Pasqualin; 1996. p.38-58.
5. Boente P, Sampaio C, Del Giglio A. Agentes antineoplásicos. In: Silva P. Farmacologia. 5a ed. Rio de Janeiro. Gumabara-Koogan; 1998. cap. 112. p.1074-80.
6. Feld R. The role of surveillance cultures in patients likely to develop chemotherapy-induced mucositis. Support Care Cancer. 1997;5(5):371-5.
7. Common Toxicity Criteria Manual Version 2.0 (1999). March 1998, updated April 30, 1999. USA: National Cancer Institute; 1999.
8. Lembersky B, Posner M. Gastrointestinal toxicities. In: Kirkwood JM, Lotze MT, Yasko JM, editors. Current cancar therapeutics. 2nd ed. Philadelphia: Churchill Livingstone; 1996. cap.27. p.326-37.
9. Gomes JAP, Lima ALH, Adan CBD. Avabação da superfície ocular In: Lima ALH, Nishiwaki-Dantas MC, Ruiz-Alves M, editores. Manual do CBO: doeças externas oculares e córnea. Rio de Janeiro: Cultura Médica; 1999. v. 1. p.57-109.
10. Kenyon KR. Anatomy and pathology of the ocular surface. Int Ophthalmol Clin. 1979;19(2):3-35.
11. Murube J. Ojo seco - dry eye. Madrid: Tecnimedia; 1997.
12. Egbert PR, Lauber S, Maurice DM. A simple conjunctival biopsy. Am J Ophthalmol. 1977;84(6):798-801.
13. Dart J. Impression cytology of the ocular surface - research tool or routine clinical investigation? Br J Ophthalmol. 1997;81(11):930.
14. Nelson JD. Impression cytology. Cornea. 1988;7(1):71-81.
15. Sidi Y, Douer D, Pinkhas J. Sicca syndrome in a patient with toxic reaction to bussulfan. JAMA. 1977;238(18):1951.
16. Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, Larooque G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988;6(9):1377-87.
17. Awidi AS. Blindness and vincristine. Ann Intern Med. 1980;93(5):781.
18. Laufman LR, Brenckman WD Jr, Stydnicki KA, Morgan ED, Collier M, Knick VB, et al. Clinical experience with leucovorin and 5-fluorouracil. Cancer. 1989;63(6 Suppl):1031-5.
19. Higa GM, Gockerman JP, Hunt AL, Jones MR, Home BJ. The use of prophylactic eye drops during high-dose cytosine arabinoside therapy. Cancer. 1991;68(8):1691-3.
20. Climent MA, Ruiz A, Llombart-Cussac A, Fernandez-Martos C, Poveda A, Dorta J et al. Weekly docetaxel in patients with advanced malignancies. Toxicity profile and activity results [abstract]. Prog Am Soc Clin Oncol. 1999;18: 119a Abstract 453.
21. Bruckner HW, Cohen J. MTX/5-FU trials in gastrointestinal and other cancers. Semin Oncol. 1983;10(2 Suppl 2):32-9.
22. Madajewicz S, Petrelli N, Rustum YM, Campbell J, Herrera L, Mittelman A, et al. Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res. 1984;44(10):4667-9.
23. Rosenoff SH, Wolf ML, Chabner BA. Pseudomonas blepharoconjunctivitis: a complication of combination chemotherapy. Arch Ophthalmol. 1974;91(6):490-1.
24. Barletta JP, Fanous MM, Margo CE. Corneal and conjunctival toxicity with low-dose cytosine arabinoside. Am J Ophthalmol. 1992;113(5):587-8.
25. Hopen G, Mondino BJ, Johnson BL, Chervenick PA. Corneal toxicity with systemic cytarabine. Am J Ophthalmol. 1981;91(4):500-4.
26. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000;18(6):1212-9.
27. Hamersley J, Luce JK, Florentz TR, Burkholder MM, Pepper JJ. Excessive lacrimation from fluorouracil treatment. JAMA. 1973;225(7):747-8.
28. Albert DM, Wong VG, Henderson ES. Ocular complications of vincristine therapy. Arch Ophthalmol. 1967;78(6):709-13.
29. Bixenman WW, Nicholls JV, Warwick OH. Oculomotor disturbances associated with 5-fluorouracil chemotherapy. Am JI Ophthalmol. 1977;83(6):789-93.
30. Kende G, Sirkin SR, Thomas PR, Fmmian Al. Blurring of vision: a previously undescribed oomplication of cyclopbosphamide therapy. Cancer. 1979;44(1):69-71.
31. Miller DF, Bay JW, Lederman RJ, Purvis JD, Rogers LR, Tornsak RL. Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant ghomas. Ophthalmology. 1985;92(3):402-6.
32. Breithaupt H, Pralle H, Eckhardt T, von Hattingberg M, Schick J, Löffer H. Clinical results and pharmacokinetics of high-dose cytosine arabinoside (ED ARA-C). Cancer. 1982;50(7):1248-57.
33. Ravindranathan MP, Paul VJ, Kuriakose ET. Cataract after busulphan treatment. Br Med J. 1972;1(5794):218-9.
34. Podos SM, Canellos GP. Lens changes in chronic granulocytic leukemia. Possible relationship to chemotherapy. Am J Ophthalmol. 1969;68(3):500-4.
35. McKeown CA, Swartz M, Blom J, Maggiano JM. Tamoxifen retinopathy. Br J Ophthalmol. 1981;65(3):177-9.
36. Kaiser-Kupfer MI, Kupfer C, Rodrigues MM. Tamoxifen retinopathy. A clinicopathologic report. Ophthalmology. 1981;88(1):89-93.
37. Shingleton BJ, Bienfang DC, Albert DM, Ensminger WD, Chandler WF, Greenberg HS. Ocular toxicity associated with high-dose carmustine. Arch Ophthalmol. 1982;100(11):1766-72.
38. Sanderson PA, Kuwabara T, Cogan DG. Optic neuropathy presumably caused by vincristine therapy. Am J Ophthalmol. 1976;81(2):146-50.
39. Fishman ML, Bean SC, Cogan DG. Optic atrophy following prophylactic chemotherapy and cranial radiation for acute lymphocytic leukemia. Am J Ophthatmol. 1976;82(4):571-6.
40. Bakemeier R, Qazi R. Basic concepts of cancer chemotherapy and principles of medical oncology. In: Rubin P, editor. Clinical oncology: a multidisciplinary approach for physicians and students. 7th ed. Philadelphia: WB Saunders; 1993. cap.8 p.105-16.
41. Martinez AJ, Mills MB, Jaceldo KB, Tio FO, Aigbivbalu IB, Hilsenbeck SB, Yee RW. Standardization of conjunctival impression cytology. Cornea. 1995;14(5):515-22.
42. Waikhom B, Fraunfelder FT, Henner WD. Severe ocular irritation and corneal deposits associated with capecitabine use. N Engl J Med. 2000;343(10):740-1. Erratum in: N Engl J Med. 2000;343(19):1428. Walkhom B [corrected to Waikhom B].
43. Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. 2003;19(4):371-5.
44. Tullo AB, Esmaeli B, Murray PI, Bristow E, Forsythe BJ, Faulkner K. Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefiamb ('Iressa', ZD1839) in Phase I and II clinical trials. Eye. 2005;19(7):729-38.
45. Turhal NS, Erdal S, Karacay S. Efficacy of treatment to relieve mucositis-induced discomfort. Support Care Cancer. 2000;8(1):55-8.
46. Connor CG, Campbell JB, Tirey WW, Steel SA, Burke JH. Modification of impression cytology for in-office use. J Am Opton Assoc. 1991;62(12):898-901.
47. Tseng SC, Hirst LW, Maumenee AE, Kenyon KR, Sun TT, Green WR. Possible mechanisms for the loss of goblet cells in mucin-deficient disorders. Ophthalmology. 1984;91(6):545-52.
48. Stenson S, Fedukowicz H, Newman R. Laboratory studies in chronic conjunctivitis. Ann Ophthalmol. 1983;15(12):1160-4.